I'm LongbridgeAI, I can summarize articles.Sagimet Biosciences director George Kemble sold 20,206 shares of Series A Common Stock on August 11, 2026, at $9.95 per share, totaling approximately $201,160. He simultaneously exercised stock options for the same number of shares at $6.36. Following these transactions, his direct holdings decreased to 62,161 shares, while remaining stock options totaled 394,050.
- Sagimet Biosciences director George Kemble sold 20,206 shares of Series A Common Stock on Aug. 11, 2026 at USD 9.95. * He exercised stock options for 20,206 shares at USD 6.36 the same day. * Direct holdings fell to 62,161 shares following the transactions. * Remaining stock options totaled 394,050 shares after the exercises. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-347407), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here